Reviews
Average rating: 4/5
Physician ( 1 )
-
5
-
4
-
3
-
2
-
1
Average rating: 4.00/5
Total Reviews: 1
-
5
-
4
-
3
-
2
-
1
Lecanemab has been shown to slow cognitive and functional decline by about 25–30% in early Alzheimer’s disease, offering meaningful though modest clinical benefit. However, treatment carries notable risks, including amyloid-related imaging abnormalities such as brain swelling and microhemorrhages, which require careful monitoring with MRI. Its use should be reserved for appropriately selected patients with confirmed amyloid pathology, weighing the potential benefits against safety concerns.
0